INNOVUS PHARMACEUTICALS, INC.: 10-Q filed 2015-11-16
What INNOVUS PHARMACEUTICALS, INC. reported in its quarterly report filed 2015-11-16 (fiscal Q3 2015): 33 published measures, 73 facts as tagged in accession 0001415889-15-003754.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-11-16
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001415889-15-003754 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All INNOVUS PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 6,782,962 | USD | |
| At 2014-12-31 | 2,081,090 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 6,473,272 | USD | |
| At 2014-12-31 | 2,507,137 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 309,690 | USD | |
| At 2014-12-31 | -426,047 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 149,521 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | -858,747 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -3,224,778 | USD | 273 |
| 2014-07-01 to 2014-09-30 | -1,126,647 | USD | 92 |
| 2014-01-01 to 2014-09-30 | -3,651,676 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -786,012 | USD | 273 |
| 2014-01-01 to 2014-09-30 | -894,912 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 9,540 | USD | 273 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 179,744 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 560,069 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 443,087 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 722,959 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 940,870 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 868,399 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -12,816 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | -14,456,745 | USD | |
| At 2014-12-31 | -11,231,967 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 52,608 | USD | |
| At 2014-12-31 | 54,511 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 831,807 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 1,209,117 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 701,391 | USD | |
| At 2014-12-31 | 520,063 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 473,360 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 744,726 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 98,766 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 395,603 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 1,917,572 | USD | |
| At 2014-12-31 | 753,970 | USD |
Goodwill carrying amount
Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 549,368 | USD | |
| At 2014-12-31 | 429,225 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 5,464,637 | USD | |
| At 2014-12-31 | 1,055,372 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 68,229 | USD | |
| At 2014-12-31 | 191,601 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 731,221 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 3,081,191 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 1,012,836 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 3,414,503 | USD | 273 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 311,204 | USD | |
| At 2014-12-31 | 265,959 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 77,385 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 317,261 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 391,788 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 565,263 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2014-09-30 | 18,885 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 128,580 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 46,241,230 | shares | |
| At 2014-12-31 | 27,112,263 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 14,720,194 | USD | |
| At 2014-12-31 | 10,778,807 | USD |
Long-term debt
Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 24,274 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-09-30 | 5,464,637 | USD | |
| At 2014-12-31 | 1,055,372 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -3,224,778 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-07-01 to 2015-09-30 | 731,221 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 3,081,191 | USD | 273 |
| 2014-07-01 to 2014-09-30 | 993,951 | USD | 92 |
| 2014-01-01 to 2014-09-30 | 3,285,923 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 24,943 | USD | 273 |
| 2014-01-01 to 2014-09-30 | 15,608 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -387,011 | USD | 273 |
| 2014-01-01 to 2014-09-30 | -71,309 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | 123,372 | USD | 273 |
| 2014-01-01 to 2014-09-30 | -211,679 | USD | 273 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-09-30 | -45,245 | USD | 273 |
| 2014-01-01 to 2014-09-30 | -52,152 | USD | 273 |
Inspect the source
- Entity
- INNOVUS PHARMACEUTICALS, INC. / CIK 0001411879
- Captured
- SEC response SHA-256
e77a101a672b8634c33f41442578c32e719835a043b28e20b379158f9e2f8bab
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001411879.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))